Elite Pharmaceuticals, Inc.
ELTP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $36 | $40 | $32 | $14 |
| % Growth | -9.7% | 25.7% | 122.7% | – |
| Cost of Goods Sold | $22 | $13 | $15 | $8 |
| Gross Profit | $14 | $27 | $17 | $6 |
| % Margin | 38.7% | 67.7% | 54.1% | 42.6% |
| R&D Expenses | $1 | $2 | $2 | $2 |
| G&A Expenses | $4 | $3 | $2 | $3 |
| SG&A Expenses | $4 | $3 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2 | $1 |
| Operating Expenses | $6 | $6 | $6 | $5 |
| Operating Income | $8 | $22 | $11 | $1 |
| % Margin | 22.6% | 54% | 34.9% | 7.6% |
| Other Income/Exp. Net | $7 | -$22 | $8 | -$12 |
| Pre-Tax Income | $16 | -$1 | $19 | -$11 |
| Tax Expense | $2 | $5 | $2 | $0 |
| Net Income | $14 | -$6 | $17 | -$11 |
| % Margin | 37.7% | -14.6% | 53.1% | -75.8% |
| EPS | 0.01 | -0.006 | 0.016 | -0.01 |
| % Growth | 281.8% | -134.6% | 255.9% | – |
| EPS Diluted | 0.01 | -0.006 | 0.016 | -0.01 |
| Weighted Avg Shares Out | 1,072 | 1,068 | 1,068 | 1,068 |
| Weighted Avg Shares Out Dil | 1,142 | 1,068 | 1,068 | 1,068 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | $16 | $0 | $20 | -$10 |
| % Margin | 44.5% | 0.3% | 62.4% | -70.2% |